Gemina Laboratories Ltd. (GLABF)
USD 0.44
(-2.91%)
USD 0.44
(-2.91%)
| Breakdown | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Cost of Revenue | 93.36 Thousand | 50.28 Thousand | 43.83 Thousand | 12.09 Thousand |
| Gross Profit | -93.36 Thousand | -50.28 Thousand | -43.83 Thousand | -12.09 Thousand |
| Operating Expenses | 5.08 Million | 5.98 Million | 4.73 Million | 633.5 Thousand |
| Selling, General and Administrative Expenses | 2.6 Million | 1.79 Million | 1.98 Million | 125.25 Thousand |
| Research and Development Expenses | 2.48 Million | 4.14 Million | 2.7 Million | 508.25 Thousand |
| Other Expenses | - | - | - | - |
| Cost and Expenses | 5.08 Million | 5.98 Million | 4.73 Million | 645.59 Thousand |
| Operating Income | -5.08 Million | -5.98 Million | -4.73 Million | -645.6 Thousand |
| Interest Expense | 19.26 Thousand | - | 539.00 | 2471.00 |
| Income Tax Expense | - | -117.61 Thousand | -184.65 Thousand | - |
| Earnings before Tax | -5.21 Million | -5.97 Million | -4.73 Million | -834.15 Thousand |
| Net Income | -5.21 Million | -5.97 Million | -4.73 Million | -834.15 Thousand |
| Earnings Per Share Basic | -0.07 | -0.10 | -0.10 | -0.02 |
| Earnings Per Share Diluted | -0.07 | -0.10 | -0.10 | -0.02 |
| Weighted Average Shares Outstanding | 72.45 Million | 60.19 Million | 47.65 Million | 50.23 Million |
| Weighted Average Shares Outstanding (Diluted) | 72.45 Million | 60.19 Million | 47.65 Million | 50.23 Million |
| Gross Margin | - | - | - | - |
| EBIT Margin | - | - | - | - |
| Profit Margin | - | - | - | - |
| EBITDA | -5.17 Million | -5.92 Million | -4.69 Million | -633.51 Thousand |
| Earnings Before Tax Margin | - | - | - | - |
| Breakdown | 2024 FY | 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | 93.36 Thousand | 26.6 Thousand | 27.41 Thousand | 20.64 Thousand | 18.7 Thousand | 14.28 Thousand |
| Gross Profit | -93.36 Thousand | -26.6 Thousand | -27.41 Thousand | -20.64 Thousand | -18.7 Thousand | -14.28 Thousand |
| Operating Expenses | 5.1 Million | 1.01 Million | 886.05 Thousand | 1.57 Million | 1.7 Million | 1.95 Million |
| Selling, General and Administrative Expenses | - | 504.37 Thousand | 608.03 Thousand | 694.77 Thousand | 812.23 Thousand | 644.13 Thousand |
| Research and Development Expenses | - | 507.56 Thousand | 278.02 Thousand | 883.35 Thousand | 896.64 Thousand | 1.31 Million |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | 5.19 Million | 1.03 Million | 886.05 Thousand | 1.57 Million | 1.7 Million | 1.95 Million |
| Operating Income | -5.19 Million | -1.03 Million | -886.05 Thousand | -1.57 Million | -1.7 Million | -1.95 Million |
| Interest Expense | 19.26 Thousand | - | 296.13 Thousand | - | - | - |
| Income Tax Expense | 2.00 | 4.00 | 296.13 Thousand | -1.00 | 3.00 | -29.52 Thousand |
| Earnings before Tax | -5.21 Million | -761.67 Thousand | -1.16 Million | -1.57 Million | -1.7 Million | -1.95 Million |
| Net Income | -5.21 Million | -761.67 Thousand | -1.16 Million | -1.57 Million | -1.7 Million | -1.95 Million |
| Earnings Per Share Basic | - | -0.01 | -0.02 | -0.02 | -0.02 | -0.03 |
| Earnings Per Share Diluted | - | -0.01 | -0.02 | -0.02 | -0.02 | -0.03 |
| Weighted Average Shares Outstanding | 72.45 Million | 72.45 Million | 73.32 Million | 73.32 Million | 69.78 Million | 60.19 Million |
| Weighted Average Shares Outstanding (Diluted) | 72.45 Million | 72.45 Million | 73.32 Million | 73.32 Million | 69.78 Million | 60.19 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | - | -1.01 Million | -858.64 Thousand | -1.55 Million | -1.69 Million | -1.94 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
9939
NWI
ALIZY
X2M
0035
5857